Overview
- U.S. International Trade Commission instituted a combined modification and enforcement proceeding after a Masimo complaint targeting Apple’s updated Blood Oxygen feature.
- The inquiry will assess infringement when an Apple Watch is paired with an iPhone, focusing on Apple’s redesign that records on the watch but shows results only in the iPhone Health app.
- Apple reintroduced the revised feature in August with approval from U.S. Customs and Border Protection, which Masimo is challenging in a separate lawsuit.
- The ITC previously blocked imports of Apple Watch Series 9 and Ultra 2 in 2023 over Masimo pulse‑oximetry patents, prompting Apple’s initial removal of the feature in the U.S.
- A California jury found Apple infringed a Masimo patent and set damages at $634 million, a verdict Apple says it will appeal, as Apple also contests the ITC ban and disputes Masimo’s domestic‑industry claims.